Henry Schein, Inc. (HSIC) Stock Analysis
Healthcare · Medical Distribution
Sell if holding. Analyst target reached at $82.13 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth.
Henry Schein distributes healthcare products and services to dental and medical practitioners globally through Global Distribution/Value-Added Services, Global Specialty Products (implants, endodontics, orthopedics), and Global Technology (practice management software) segments,... Read more
Sell if holding. Analyst target reached at $82.13 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Henry Schein, Inc.
About Henry Schein, Inc.
Henry Schein served more than one million dental and medical customers across 34 countries and territories in fiscal 2025, with the Dental category representing 52.0% of consolidated net sales and Medical 32.5%. The company's three segments—Global Distribution and Value-Added Services (84.5% of net sales), Global Specialty Products (11.7%), and Global Technology (5.1%)—employed over 25,000 people at year-end, with 52% of the workforce outside the United States. Henry Schein operates 38 distribution centers and 17 manufacturing facilities globally.
Henry Schein generates revenue from consumable and equipment distribution to dental and medical practitioners, supplemented by specialty product manufacturing (dental implants, endodontics, orthodontics, and orthopedics) and practice management software. The Global Technology segment had approximately 95,000 active practice users and 324,000 consumers at December 27, 2025. In U.S. dental distribution, primary competitors are Patterson Dental (a division of Patterson Companies) and Benco Dental Supply; in U.S. medical distribution, McKesson Corporation and Medline Industries. Outside the U.S., the company positions itself as the only global dental distributor to practices, competing against regional players including Cadence Group, DD Group, Lifco AB, and Planmeca Group. In fiscal 2025, the top 10 Global Distribution and Value-Added Services suppliers accounted for approximately 24% of aggregate purchases and the single largest supplier 4%, with the company characterizing no single supplier as material. Supplier rebates tied to volume growth targets represent an additional income stream subject to competitive and supply conditions.
Show full overview
Henry Schein's distribution model faces structural headwinds from online price transparency and potential regulatory reimbursement shifts. The 10-K notes that potential adoption of the One Big Beautiful Bill Act could affect Medicare and Medicaid eligibility, which may impact practitioner demand for distributed products. On cybersecurity, an October 2023 cyberattack disrupted North American and European dental and medical distribution operations, with residual financial impact extending into fiscal 2024—the filing acknowledges this may mark the company as a more vulnerable future target. In January 2025, funds affiliated with KKR invested $250 million at approximately $76.10 per share under a Strategic Partnership Agreement permitting KKR to acquire up to 19.9% of outstanding shares, a large-block counterparty relationship the filing acknowledges could create unintended conflicts or uncertainty about strategic direction.
See also: Healthcare · Medical Distribution
From Henry Schein, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — Henry Schein, Inc.
Latest news
- NEWS Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound? - MSN — MSN negative
- NEWS Henry Schein Inc. (HSIC): David Einhorn Is Buying This Health Stock - Yahoo Finance — Yahoo Finance positive
- NEWS Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term - Yahoo Finance — Yahoo Finance positive
- NEWS Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance neutral
- NEWS Henry Schein (HSIC) reports next week: Wall Street expects earnings growth - MSN — MSN positive
Generated 2026-06-17T09:02:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $82.13 — A.R:R is negative (-0.2) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak growth. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $77.65. Score 5.0/10, moderate confidence.
Take-profit target: $80.66 (-0.7% upside). Prior stop was $77.65. Stop-loss: $77.65.
Analyst target reached - limited upside remaining; Weak growth; Overbought (RSI 78).
Henry Schein, Inc. trades at a P/E of 24.5 (forward 13.7). TrendMatrix value score: 5.9/10. Verdict: Sell.
24 analysts cover HSIC with a consensus score of 3.8/5. Average price target: $88.
What does Henry Schein, Inc. do?Henry Schein distributes healthcare products and services to dental and medical practitioners globally through Global...
Henry Schein distributes healthcare products and services to dental and medical practitioners globally through Global Distribution/Value-Added Services, Global Specialty Products (implants, endodontics, orthopedics), and Global Technology (practice management software) segments, serving over one million customers worldwide. Top 10 suppliers in distribution accounted for ~25% of aggregate purchases; single largest supplier ~4%. No single customer represents a material concentration.